CRIS Current Research Information System

TOVOLI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.427
EU - Europa 3.347
AS - Asia 2.005
AF - Africa 277
SA - Sud America 22
OC - Oceania 7
Totale 11.085
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.401
IT - Italia 718
GB - Regno Unito 671
CN - Cina 670
SG - Singapore 636
SE - Svezia 569
DE - Germania 458
VN - Vietnam 368
IE - Irlanda 198
IN - India 196
TG - Togo 148
CH - Svizzera 133
RU - Federazione Russa 117
FR - Francia 96
FI - Finlandia 76
UA - Ucraina 68
BG - Bulgaria 56
ZA - Sudafrica 53
EE - Estonia 44
JO - Giordania 32
CI - Costa d'Avorio 30
ID - Indonesia 30
NG - Nigeria 28
CA - Canada 24
HR - Croazia 24
BE - Belgio 23
NL - Olanda 17
ES - Italia 15
MK - Macedonia 11
AT - Austria 10
HK - Hong Kong 10
TR - Turchia 10
TW - Taiwan 10
GR - Grecia 9
RO - Romania 9
CL - Cile 8
JP - Giappone 7
BR - Brasile 6
CZ - Repubblica Ceca 6
DZ - Algeria 6
EG - Egitto 6
AU - Australia 5
CO - Colombia 5
KR - Corea 5
PH - Filippine 5
PL - Polonia 5
KZ - Kazakistan 4
LT - Lituania 4
PK - Pakistan 4
SC - Seychelles 4
DK - Danimarca 3
IR - Iran 3
LB - Libano 3
PT - Portogallo 3
UZ - Uzbekistan 3
IL - Israele 2
KE - Kenya 2
NZ - Nuova Zelanda 2
AM - Armenia 1
AR - Argentina 1
BD - Bangladesh 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
HU - Ungheria 1
IQ - Iraq 1
KH - Cambogia 1
LK - Sri Lanka 1
MD - Moldavia 1
MX - Messico 1
MY - Malesia 1
NO - Norvegia 1
RS - Serbia 1
SA - Arabia Saudita 1
Totale 11.085
Salva come PNG Salva come JPEG
Città #
Fairfield 640
Southend 597
Singapore 564
Chandler 526
Ashburn 463
Santa Clara 323
Woodbridge 294
Wilmington 278
Seattle 266
Houston 244
Dong Ket 223
Princeton 203
Cambridge 201
Dublin 198
Boardman 184
Ann Arbor 159
Bologna 159
Lomé 148
Bern 125
New York 77
Berlin 67
Helsinki 62
Westminster 61
Beijing 60
Los Angeles 56
Sofia 52
Padova 50
Nanjing 49
Turin 45
Jinan 41
Bremen 38
San Diego 36
Amman 32
Redmond 32
Milan 31
Abidjan 30
Jakarta 30
Des Moines 29
Rome 29
Shenyang 29
Abeokuta 28
Redwood City 27
Saint Petersburg 27
Washington 24
Shanghai 23
Florence 22
Jacksonville 22
Brussels 21
Falls Church 20
Guangzhou 17
London 17
Hebei 16
Tianjin 16
Chicago 15
Changsha 14
Frankfurt am Main 14
Lappeenranta 14
Munich 14
Mülheim 14
Nanchang 13
Olalla 13
Toronto 13
Bühl 12
Moscow 12
Hangzhou 11
Medford 11
Paris 11
Zhengzhou 11
Haikou 10
Skopje 10
Vienna 10
Wuhan 10
Falkenstein 9
Jiaxing 9
Mountain View 9
Ningbo 9
Norwalk 9
Qingdao 9
Shenzhen 9
Shijiazhuang 9
Amsterdam 8
Dearborn 8
Kunming 8
Phoenix 8
Prineville 8
Pune 8
Taipei 8
Germantown 7
Harbin 7
Lübeck 7
Napoli 7
Ottawa 7
Parma 7
Taiyuan 7
Taizhou 7
Chongqing 6
Dongguan 6
Dulles 6
Forlì 6
Fort Worth 6
Totale 7.457
Salva come PNG Salva come JPEG
Nome #
Ablation for hepatocellular carcinoma: beyond the standard indications 199
Serological tests in gluten sensitivity (nonceliac gluten intolerance). 195
null 164
Imaging-based diagnosis of benign lesions and pseudolesions in the cirrhotic liver 161
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention 154
A case of inflammatory ascites. 144
Cholangiocarcinoma: From risk to prevention? 143
Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis 142
Monofocal hepatocellular carcinoma: How much does size matter? 140
Celiac disease diagnosed through screening programs in at-risk adults is not associated with worse adherence to the gluten-free diet and might protect from osteopenia/osteoporosis 139
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 135
Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis 135
Antibodies to deamidated gliadin peptides: an accurate predictor of coeliac disease in infancy. 135
Clinical and diagnostic aspects of gluten related disorders 133
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 132
Deamidated gliadin Peptide antibodies as a routine test for celiac disease: a prospective analysis. 131
A relative deficiency of lysosomal acid lypase activity characterizes non-alcoholic fatty liver disease 131
Clinical and immunological features of celiac disease in patients with Type 1 diabetes mellitus. 129
Metabolic disorders across hepatocellular carcinoma in Italy 128
Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: A multicenter real-life study 127
An uncommon focal liver lesion: Intrahepatic splenosis 124
An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib 123
A seroimmunological profile of erosive hand osteoarthritis. 123
Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet: beyond traditional metabolic factors 122
Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib 121
More therapeutic alternatives for chronic idiopathic urticaria? 120
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. 119
New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: A new diagnostic algorithm 119
null 117
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 116
Autoimmune liver disorders and small-vessel vasculitis:four case reports and review of the literature 115
From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma 115
null 114
Imaging of colorectal liver metastases: New developments and pending issues 114
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients 114
Systemic treatments for hepatocellular carcinoma: challenges and future perspectives 113
Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma 113
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 112
Rheumatoid arthritis: New monoclonal antibodies 108
Thrombotic thrombocytopenic purpura mimicking an acute meningoencephalitis. 108
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 108
Effect of gluten free diet on immune response to gliadin in patients with non-celiac gluten sensitivity. 108
Pattern of macrovascular invasion in hepatocellular carcinoma 108
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 104
Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma 103
Benefits, Open questions and Challenges of the use of Ultrasound in the COVID-19 pandemic eraThe views of a panel of worldwide international experts 103
Eosinophilic granulomatosis with polyangiitis of the major salivary glands: a case of sialadenitis in a young patient. 98
The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy 97
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 94
Old and new serological tests for celiac disease screening. 93
Lung Ultrasound Is Often, but Not Always, Normal in Healthy Subjects: Considerations for {COVID}-19 Pandemic 93
Lenvatinib mesylate to treat hepatocellular carcinoma 92
Treatment of combined hepatocellular and cholangiocarcinoma 92
Hepatocellular carcinoma in non alcoholic fatty liver disease 91
Non-celiac gluten sensitivity: questions still to be answered despite increasing awareness. 88
Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019 87
Telomerase reactivation is associated with hepatobiliary and pancreatic cancers 87
Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area 85
Hot topics in hepatocellular carcinoma 85
Nailfold capillaroscopy in primary biliary cirrhosis: a useful tool for the early diagnosis of scleroderma. 84
Fulminant type 1 autoimmune hepatitis in a recently diagnosed celiac disease patient. 83
Regorafenib for the treatment of hepatocellular carcinoma 83
Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: A tale of multiple confounders 83
null 82
Gut-liver axis: an immune link between celiac disease and primary biliary cirrhosis. 81
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 81
Anti-ganglioside antibodies and celiac disease 81
What Future for Ultrasound in Medicine? 80
Sensitivity of autologous serum skin test for chronic autoimmune urticaria 79
Fibromyalgia and coeliac disease: a media hype or an emerging clinical problem? 79
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma (Targeted Oncology, (2020), 15, 6, (773-785), 10.1007/s11523-020-00757-3) 78
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 76
null 75
Non-alcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role 75
SAT-453-Effects of sorafenib on pancreatic volume and their clinical implications in patients with hepatocellular carcinoma 74
Ultrasound in the Assessment of Tumor Response in the Age of Targeted and Immuno-Oncology TherapiesBack to the Future 73
null 72
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. 71
Hepatic Steatosis in Patients with Celiac Disease: The Role of Packaged Gluten-Free Foods 69
Surrogate Markers for Antimitochondrial Antibody-Negative Primary Biliary Cholangitis 69
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 69
Anti-neutrophil cytoplasm antibodies (ANCA) in autoimmune diseases: A matter of laboratory technique and clinical setting 69
Hereditary breast cancer: Screening and risk reducing surgery 68
Experience with regorafenib in the treatment of hepatocellular carcinoma 68
Immunotherapy with checkpoint inhibitors for hepatocellular carcinoma: Where are we now? 67
Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery 67
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial 66
Autoantibodies to speckled protein family in primary biliary cholangitis 66
Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5) 66
The duration of the conventional chemoembolization for hepatocellular carcinoma: factors affecting the procedural time 63
Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma 63
Current guidelines for the management of celiac disease: A systematic review with comparative analysis 59
The changing scenario of hepatocellular carcinoma in Italy: an update 59
Hepatocellular adenoma: An unsolved diagnostic enigma 59
Unexpected newborns in the liver : hemangiomatosis onset after hepatic resection of a giant cavernous hemangioma 58
Contrast-enhanced ultrasound of the liver in colorectal cancer: A useful tool in the right patient 58
Tocilizumab: From rheumatic diseases to covid-19 58
Therapeutic targets to watch for fibromyalgia 57
Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis 57
Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease 56
Totale 9.924
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.978
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.978
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.283 0 0 0 0 0 170 241 269 284 166 76 77
2020/20211.548 209 87 64 57 191 106 30 77 134 79 68 446
2021/20222.065 139 42 94 108 175 112 50 167 106 154 646 272
2022/20232.589 230 357 126 305 164 212 164 133 441 67 170 220
2023/20241.049 49 141 76 77 112 216 84 86 65 73 48 22
2024/20252.007 168 424 415 295 515 190 0 0 0 0 0 0
Totale 11.509